Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

January 17, 2017

Primary Completion Date

August 27, 2019

Study Completion Date

March 16, 2021

Conditions
Recurrent Platinum Resistant Ovarian Cancer
Interventions
DRUG

cediranib and olaparib

"Cediranib tablets oral dose 30 mg once daily; Olaparib(Lynparza) tablet 200 mg twice daily~Dose reduction for both products is allowed"

Trial Locations (25)

10032

Research Site, New York

14642

Research Site, Rochester

21204

Research Site, Towson

27103

Research Site, Winston-Salem

28204

Research Site, Charlotte

30265

Research Site, Newnan

30901

Research Site, Augusta

32804

Research Site, Orlando

33136

Research Site, Miami

33176

Research Site, Miami

36604

Research Site, Mobile

37920

Research Site, Knoxville

46804

Research Site, Fort Wayne

59101

Research Site, Billings

66205

Research Site, Westwood

70433

Research Site, Covington

90048

Research Site, West Hollywood

90241

Research Site, Downey

92123

Research Site, San Diego

92868

Research Site, Orange

94115

Research Site, San Francisco

94904

Research Site, Greenbrae

98104

Research Site, Seattle

99508

Research Site, Anchorage

02215

Research Site, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Myriad Genetic Laboratories, Inc.

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

AstraZeneca

INDUSTRY